# US 2003/0207807 A1 · Feline hepatocyte growth factor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0207807 A1
- Document ID: US20030207807A1
- Status: Published application
- Kind: A1
- Application number: 10/297,158
- Filed: 2002-12-02
- Published: 2003-11-06
- Earliest claimed: 2000-05-31
- Assignees: Nippon Zenyaku Kogyo Co., Ltd.
- Inventors: Masashi Miyake; Shigehiro Iwabuchi; Yasuyuki Suzuta
- Web page: https://patentgrep.com/patent/US20030207807A1

## CPC

- C07K 14/4753: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A feline hepatocyte growth factor gene and a 15 base pairs-deleted feline hepatocyte growth factor gene. These genes encode the following protein (a) or (b): (a) a protein having an amino acid sequence shown in SEQ ID NO: 2 or 4; and (b) a protein having an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 2 or 4, and having a feline hepatocyte growth factor activity. The feline hepatocyte growth factor and the 5 amino acids-deleted feline hepatocyte growth factor are useful for the treatment of liver diseases, kidney diseases, lung diseases, digestive diseases, cardiocirculatory diseases or cranial nerve diseases.

## Claims

### Claim 1

A recombinant protein of the following (a) or (b):
(a) a protein having an amino acid sequence shown in SEQ ID NO: 2 or 4; and
(b) a protein having an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 2 or 4, and having a feline hepatocyte growth factor activity.

### Claim 2

A gene encoding the following protein (a) or (b):
(a) a protein having an amino acid sequence shown in SEQ ID NO: 2 or 4; and
(b) a protein having an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 2 or 4, and having a feline hepatocyte growth factor activity.

### Claim 3

A gene comprising DNA of the following (c) or (d):
(c) DNA comprising a nucleotide sequence shown in SEQ ID NO: 1 or 3; and
(d) DNA hybridizing with the DNA comprising the nucleotide sequence shown in SEQ ID NO: 1 or 3 under stringent conditions, and encoding a protein having a feline hepatocyte growth factor activity.

### Claim 4 (depends on 2, 3)

A recombinant vector comprising the gene according to claim 2 or 3.

### Claim 5 (depends on 4)

A transformant comprising the recombinant vector according to claim 4.

### Claim 6 (depends on 5)

A method for producing a feline hepatocyte growth factor, which is characterized in that it comprises culturing the transformant according to claim 5 and collecting the feline hepatocyte growth factor from the obtained culture.

### Claim 7 (depends on 2, 3)

A reagent for detecting a feline hepatocyte growth factor comprising at least a fragment of the gene according to claim 2 or 3.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising the recombinant feline hepatocyte growth factor according to claim 1.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, which is used for treatment of liver diseases, kidney diseases, lung diseases, bone diseases, digestive diseases, cardiocirculatory diseases or cranial nerve diseases.
